Neuralgia Treatment Market Report 2026

The neuralgia treatment market size has grown strongly in recent years. It will grow from $2.43 billion in 2025 to $2.58 billion in 2026 at a compound annual growth rate (CAGR) of 6.1%. The growth in the historic period can be attributed to rising prevalence of diabetic neuropathy cases, early adoption of anticonvulsant medications, growth in opioid-based pain treatment, increased awareness of neuralgia symptoms, expansion of hospital-based pain clinics.

The neuralgia treatment market size is expected to see strong growth in the next few years. It will grow to $3.38 billion in 2030 at a compound annual growth rate (CAGR) of 7%. The growth in the forecast period can be attributed to growth in minimally invasive surgical pain treatments, rising demand for spinal cord stimulation devices, increasing use of targeted topical therapies, expansion of telemedicine-based neuralgia care, development of next-generation non-opioid pain medications. Major trends in the forecast period include growing use of drug-based neuralgia management, increasing adoption of nerve block and decompression procedures, rising demand for topical pain relief therapies, expansion of spinal cord stimulation for chronic neuralgia, increasing focus on early diagnosis and long-term pain management.

The increasing prevalence of chronic diseases, including diabetes, is expected to drive the growth of the neuralgia treatment market in the coming years. Chronic diseases are long-term conditions that last a year or more, requiring ongoing medical care and often limiting daily activities. Diabetes, a metabolic disorder characterized by elevated blood glucose levels, can lead to diabetic neuropathy, a type of nerve damage treatable with neuralgia therapies. For example, in March 2024, the Office for Health Improvement and Disparities, a UK-based government department, reported that between March 2022 and March 2023, the percentage of individuals with type 1 diabetes receiving all eight recommended care processes increased by 22%, and for type 2 diabetes, it rose by 21%. Additionally, the proportion of patients achieving target HbA1c levels reached 37.9%, the highest value ever reported by the National Diabetes Audit (NDA). Therefore, the growing prevalence of chronic diseases, particularly diabetes, is fueling the neuralgia treatment market.

Leading companies in the neuralgia treatment market are developing innovative solutions such as peripheral nerve-targeted delivery systems to improve therapeutic precision, reduce chronic neuropathic pain, and enhance long-term patient outcomes. These delivery systems are specialized platforms that concentrate analgesic or neuromodulatory agents directly at affected nerves, providing more accurate pain modulation while minimizing systemic exposure. For example, in April 2023, GlaxoSmithKline Pharmaceuticals Ltd., an India-based pharmaceutical company, launched Shingrix in India, the world’s first non-live recombinant subunit vaccine. Shingrix is designed to prevent shingles and post-herpetic neuralgia in adults aged 50 years and older, administered intramuscularly in two doses. The vaccine combines the antigen glycoprotein E with the AS01B adjuvant system to elicit a strong, long-lasting immune response, counteracting age-related immune decline. Clinical trials demonstrated 97% efficacy in preventing shingles, as well as effectiveness in preventing post-herpetic neuralgia, a painful complication of the disease.

In September 2025, Semnur Pharmaceuticals, Inc., a US-based developer of non-opioid, targeted pain therapeutics, completed a merger with Denali Capital Acquisition Corp., a US-based SPAC, for an undisclosed amount. This merger enables Semnur to become a publicly traded company and accelerate the development and commercialization of its non-opioid pain management programs across acute, chronic, and neuropathic pain indications.

Major companies operating in the neuralgia treatment market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Mylan N.V., Biogen Inc., Boehringer Ingelheim International GmbH, Sun Pharmaceutical Industries Limited, Purdue Pharma, Dr. Reddy's Laboratories, Cipla Limited, Hikma Pharmaceuticals plc, Zydus Lifesciences Ltd., Lupin Limited, Mallinckrodt Pharmaceuticals, Glenmark Pharmaceuticals.

North America was the largest region in the neuralgia treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neuralgia treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the neuralgia treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are affecting the neuralgia treatment market by increasing costs for imported medications, topical treatments, and neuromodulation devices such as spinal cord stimulators. Hospitals, clinics, and ambulatory surgery centers in regions dependent on imported pharmaceuticals - especially Asia-Pacific and Europe - face higher procurement costs and longer supply delays. Drug-based treatments (such as anticonvulsants and antidepressants) and surgical tools used for nerve block procedures are the most impacted. However, tariffs are encouraging domestic production of pain management drugs and device components, supporting regional manufacturing growth and reducing long-term dependency on external suppliers.

The neuralgia treatment market research report is one of a series of new reports that provides neuralgia treatment market statistics, including neuralgia treatment industry global market size, regional shares, competitors with a neuralgia treatment market share, detailed neuralgia treatment market segments, market trends and opportunities, and any further data you may need to thrive in the neuralgia treatment industry. This neuralgia treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Neuralgia treatment refers to medical interventions aimed at managing chronic nerve pain, which can result from injury, infection, or underlying medical conditions. The goal of treatment is to alleviate symptoms, slow disease progression, and prevent complications.

The main types of neuralgia treatments include drug-based therapies and surgical interventions. Drug-based treatments involve the use of medications to reduce pain, inflammation, or nerve damage. These medications are prescribed for various indications, such as diabetic neuropathy, intercostal neuralgia, occipital neuralgia, peripheral neuralgia, and postherpetic neuralgia. Distribution channels for these treatments include drug stores, hospital pharmacies, online pharmacies, and retail pharmacies. Neuralgia treatments are utilized by hospitals, clinics, ambulatory surgery centers, and other healthcare settings to provide effective pain management and improve patient quality of life.

The neuralgia treatment market consists of revenues earned by entities by providing blood tests, magnetic resonance imaging (MRI), nerve conduction velocity tests, physical therapies and alternative therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The neuralgia treatment market also includes sales of anticonvulsant medications, pain relievers, antidepressants and antiseizure medications. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.